SciClone Pharmaceuticals (SCLN +30.7%) posted better-than-expected Q4 results, helped by a...


SciClone Pharmaceuticals (SCLN +30.7%) posted better-than-expected Q4 results, helped by a widened product portfolio boosted by its NovaMed acquisition and growth in sales of its key drug Zadaxin, and raised its 2012 forecast to EPS of $0.72-$0.78 on revenue of $165M-$170M vs. estimates of $0.43 on revenue of $168M.

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs